Form 4 for GPCR Structure Therapeutics Inc.
Accepted 2023-02-09 00:00:00 ET · period of report 2023-02-07 · accession 0000315066-23-002162 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2023-02-09 | 2023-02-07 | GPCR | FMR LLC | See Remark 1 | C - Cnv Deriv | — | +5.82M | 57.5K | New | — |
| DMI | 2023-02-09 | 2023-02-07 | GPCR | FMR LLC | See Remark 1 | C - Cnv Deriv | — | -5.82M | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2023-02-07 | C | A | 3,572,022 | — | 3,572,022 | I Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned | — | — | (F1) On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| 2 | Common | Ordinary Shares | 2023-02-07 | C | A | 7,411 | — | 75,088 | I F-Prime Capital Partners Life Sciences Advisors Fund VI LP | — | — | (F1) On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| 3 | Common | Ordinary Shares | 2023-02-07 | C | A | 10,154 | — | 67,677 | I F-Prime Capital Partners Life Sciences Advisors Fund VI LP | — | — | (F1) On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| 4 | Common | Ordinary Shares | 2023-02-07 | C | A | 568,098 | — | 4,140,120 | I Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned | — | — | (F1) On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| 5 | Common | Ordinary Shares | 2023-02-07 | C | A | 414,621 | — | 4,554,741 | I Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned | — | — | (F1) On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| 6 | Common | Ordinary Shares | 2023-02-07 | C | A | 214,663 | — | 4,769,404 | I Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned | — | — | (F1) On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| 7 | Common | Ordinary Shares | 2023-02-07 | C | A | 6,947 | — | 82,035 | I F-Prime Capital Partners Life Sciences Advisors Fund VI LP | — | — | (F1) On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| 8 | Common | Ordinary Shares | 2023-02-07 | C | A | 965,115 | — | 965,115 | I F-Prime Capital Partners Life Sciences Fund VI LP | — | — | (F1) On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| 9 | Common | Ordinary Shares | 2023-02-07 | C | A | 57,523 | — | 57,523 | I F-Prime Capital Partners Life Sciences Advisors Fund VI LP | — | — | (F1) On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| 10 | Derivative | Series A Convertible Preferred Shares | 2023-02-07 | C | D | 3,572,022 | — | 0 | I Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned | — · — to — | 3,572,022 Ordinary Shares | (F1) On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| 11 | Derivative | Series B-1 Convertible Preferred Shares | 2023-02-07 | C | D | 214,663 | — | 0 | I Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned | — · — to — | 214,663 Ordinary Shares | (F1) On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| 12 | Derivative | Series B-1 Convertible Preferred Shares | 2023-02-07 | C | D | 6,947 | — | 0 | I F-Prime Capital Partners Life Sciences Advisors Fund VI LP | — · — to — | 6,947 Ordinary Shares | (F1) On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| 13 | Derivative | Series B Convertible Preferred Shares | 2023-02-07 | C | D | 7,411 | — | 0 | I F-Prime Capital Partners Life Sciences Advisors Fund VI LP | — · — to — | 7,411 Ordinary Shares | (F1) On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| 14 | Derivative | Series A+ Convertible Preferred Shares | 2023-02-07 | C | D | 568,098 | — | 0 | I Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned | — · — to — | 568,098 Ordinary Shares | (F1) On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| 15 | Derivative | Series B Convertible Preferred Shares | 2023-02-07 | C | D | 414,621 | — | 0 | I Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned | — · — to — | 414,621 Ordinary Shares | (F1) On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| 16 | Derivative | Series A+ Convertible Preferred Shares | 2023-02-07 | C | D | 10,154 | — | 0 | I F-Prime Capital Partners Life Sciences Advisors Fund VI LP | — · — to — | 10,154 Ordinary Shares | (F1) On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| 17 | Derivative | Series A Convertible Preferred Shares | 2023-02-07 | C | D | 965,115 | — | 0 | I F-Prime Capital Partners Life Sciences Fund VI LP | — · — to — | 965,115 Ordinary Shares | (F1) On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |
| 18 | Derivative | Series A Convertible Preferred Shares | 2023-02-07 | C | D | 57,523 | — | 0 | I F-Prime Capital Partners Life Sciences Advisors Fund VI LP | — · — to — | 57,523 Ordinary Shares | (F1) On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares. |